GO:1904294 positive regulation of ERAD pathway: Protein Quality Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904294 (positive regulation of ERAD pathway) describes any process that activates or increases the frequency, rate, or extent of endoplasmic reticulum-associated degradation (ERAD), a central protein quality-control system of the secretory pathway.
• Positive regulation of ERAD is essential for clearing misfolded proteins from the endoplasmic reticulum (ER) and for maintaining hepatic inclusions and fibrinogen biogenesis, as shown for the SEL1L-HRD1 complex.
• ERAD activity is co-opted in cancer: OTUB1 deubiquitinates PD-L1 to prevent its ERAD-mediated degradation, promoting immunosuppression, while TRIM25 targets Keap1 for ERAD to activate Nrf2 and support hepatocellular carcinoma growth.
• ERAD also shapes immunity: SEL1L preserves CD8+ T-cell survival by fine-tuning PERK signaling and the IL-15 receptor-mTORC1 axis, and B4GALT5 downregulates MHC-I through ERAD to limit CD8+ T-cell responses in pancreatic ductal adenocarcinoma.
• UBX domain-containing protein 6 (UBXD6) is required for autophagy induction and inflammation control in macrophages, linking positive ERAD regulation to innate immune homeostasis.
• Key experimental approaches to study positive regulation of ERAD include genetic selection for transmembrane domain mutations in HRD1, cross-presentation assays, and CRISPR-based knockout, point-mutation, knock-in, and overexpression models.
Description
The Gene Ontology term GO:1904294, positive regulation of ERAD pathway, captures any biological process that activates or increases the frequency, rate, or extent of endoplasmic reticulum-associated degradation (ERAD). ERAD is a conserved protein quality-control pathway that recognizes terminally misfolded or regulated proteins in the endoplasmic reticulum (ER), retrotranslocates them to the cytosol, and delivers them to the proteasome for degradation. Because ERAD sits at the intersection of protein folding, secretion, and cellular stress responses, its positive regulation is critical for proteostasis and for shaping physiological outputs such as hepatic fibrinogen biogenesis and immune cell survival. Researchers study positive regulation of ERAD to understand how cells adapt to ER stress, how immune checkpoint proteins and antigen presentation are controlled, and how cancer cells exploit ERAD to evade immunity. The pathway is also a therapeutic target: modulating ERAD activity can alter the half-life of oncoproteins, immune receptors, and misfolded disease proteins. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, diseases, and experimental methods associated with GO:1904294. By focusing on real experimental evidence, we highlight how positive regulators of ERAD such as SEL1L-HRD1, OTUB1, TRIM25, and UBXD6 influence cell fate and disease. The content is designed for both human readers and generative-AI retrieval, with inline citations to primary literature and a structured presentation of ontology-specific knowledge.
positive regulation of ERAD pathway At A Glance
| GO ID | GO:1904294 |
|---|---|
| GO term | positive regulation of ERAD pathway |
| Ontology | biological_process |
| Synonym | activation of ERAD pathway; upregulation of ERAD pathway; positive regulation of endoplasmic reticulum-associated degradation |
| Major function | Increases the frequency, rate, or extent of ER-associated degradation of misfolded or regulated proteins |
| Related pathway | ERAD (endoplasmic reticulum-associated degradation), a branch of protein quality control |
| Key complexes | SEL1L-HRD1 complex, which is central to ERAD and hepatic fibrinogen biogenesis |
| Disease relevance | Cancer immunosuppression, antigen cross-presentation, hepatic inclusions, and immune homeostasis |
| Research methods | Genetic selection, cross-presentation assays, CRISPR knockout/knock-in, proteomics, and imaging |
What Is GO:1904294?
In our own words, GO:1904294 (positive regulation of ERAD pathway) refers to any process that activates or increases the frequency, rate, or extent of the ERAD pathway. This includes molecular events that enhance substrate recognition, retrotranslocation, ubiquitination, or proteasomal delivery during ER-associated degradation, as well as signaling inputs that upregulate ERAD capacity under stress or developmental cues.
Why Is positive regulation of ERAD pathway Important in Cell Biology?
Positive regulation of ERAD is important because it determines the fate of proteins that fail to fold in the ER, thereby protecting cells from proteotoxic stress and influencing secretion, immunity, and cancer progression. Dysregulation of ERAD positive regulators can lead to accumulation of misfolded proteins, altered immune surveillance, and tumor growth, making this GO term a focal point for both basic cell biology and translational research.
• Maintains ER proteostasis by enhancing clearance of misfolded proteins through the SEL1L-HRD1 complex.
• Supports hepatic fibrinogen biogenesis and prevents hepatic inclusions.
• Promotes cancer cell survival by targeting Keap1 for degradation and activating Nrf2.
• Drives immunosuppression by preventing ERAD-mediated degradation of PD-L1 via OTUB1.
• Limits CD8+ T-cell responses in pancreatic ductal adenocarcinoma by downregulating MHC-I through ERAD.
• Preserves CD8+ T-cell survival and homeostasis by fine-tuning PERK signaling and the IL-15 receptor-mTORC1 axis.
• Controls autophagy induction and inflammation in macrophages through UBXD6.
• Influences antigen export to the cytosol during cross-presentation.
• Provides a mechanism for genetic selection of transmembrane domain mutations in HRD1.
• Offers therapeutic targets for modulating immune checkpoint stability and tumor immunity.
What Happens During positive regulation of ERAD pathway?
Substrate recognition and ERAD complex assembly
In simple terms: The cell first identifies which misfolded proteins need to be destroyed and assembles the machinery to do it.
Positive regulation of ERAD begins with enhanced recognition of misfolded or regulated substrates in the ER lumen or membrane. The SEL1L-HRD1 complex is a central ERAD component that recognizes substrates and coordinates their delivery to the retrotranslocation machinery. Genetic selection for transmembrane domain mutations in HRD1 underscores the importance of Hrd1 complex integrity during ERAD, showing that positive regulation requires a functional complex.
Retrotranslocation and ubiquitination
In simple terms: The tagged protein is pulled out of the ER and marked with ubiquitin for destruction.
Once substrates are recognized, they are retrotranslocated to the cytosol and ubiquitinated. Positive regulation of ERAD increases the efficiency of these steps. For example, OTUB1 prevents ER-associated degradation of PD-L1 by deubiquitination, illustrating that the balance of ubiquitination and deubiquitination controls ERAD flux. TRIM25 promotes degradation of Keap1 through ERAD, linking ubiquitin ligase activity to positive regulation of the pathway.
Proteasomal delivery and degradation
In simple terms: The marked protein is delivered to the proteasome and chopped up.
After retrotranslocation and ubiquitination, substrates are delivered to the proteasome for degradation. Positive regulation of ERAD enhances this delivery, thereby reducing ER stress. In hepatic cells, SEL1L-HRD1 ERAD regulates fibrinogen biogenesis and prevents the accumulation of hepatic inclusions, demonstrating the physiological importance of efficient proteasomal delivery.
Integration with stress and immune signaling
In simple terms: ERAD activity is tuned by stress and immune signals to match cellular needs.
Positive regulation of ERAD is integrated with stress and immune signaling. SEL1L preserves CD8+ T-cell survival by fine-tuning PERK signaling and the IL-15 receptor-mediated mTORC1 axis. UBXD6 is essential for autophagy induction and inflammation control in macrophages, linking ERAD regulation to innate immunity. B4GALT5 downregulates MHC-I through ERAD to inhibit CD8+ T-cell responses in pancreatic ductal adenocarcinoma.
Antigen export during cross-presentation
In simple terms: ERAD helps move antigens out of the ER so immune cells can present them.
Positive regulation of ERAD also participates in antigen export to the cytosol during cross-presentation, a process critical for CD8+ T-cell activation. This highlights how ERAD activity can be co-opted for immune surveillance beyond protein quality control.
Key Genes Involved in GO:1904294 positive regulation of ERAD pathway
The following genes and proteins are experimentally implicated in positive regulation of ERAD pathway, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SEL1L | Core component of the SEL1L-HRD1 ERAD complex; regulates hepatic inclusions and fibrinogen biogenesis | Studied in ERAD substrate recognition and CD8+ T-cell survival |
| HRD1 (SYVN1) | E3 ubiquitin ligase in the HRD1 complex; essential for ERAD | Genetic selection for transmembrane domain mutations underscores complex integrity |
| OTUB1 | Deubiquitinating enzyme that prevents ERAD of PD-L1 | Target for cancer immunosuppression research |
| TRIM25 | E3 ubiquitin ligase that targets Keap1 for ERAD, activating Nrf2 | Promotes hepatocellular carcinoma survival and growth |
| UBXD6 | UBX domain-containing protein essential for autophagy induction and inflammation control | Links ERAD regulation to macrophage immunity |
| B4GALT5 | Downregulates MHC-I through ERAD in PDAC | Inhibits CD8+ T-cell response; potential immunotherapy target |
| PD-L1 (CD274) | Immune checkpoint protein whose ERAD degradation is prevented by OTUB1 | Central to cancer immunosuppression |
| Keap1 | Substrate of TRIM25-mediated ERAD; regulates Nrf2 | Target in hepatocellular carcinoma |
| MHC-I | Downregulated via ERAD by B4GALT5 in PDAC | Affects antigen presentation and CD8+ T-cell response |
| PERK (EIF2AK3) | Signaling node fine-tuned by SEL1L in CD8+ T cells | Links ERAD to integrated stress response |
| IL-15 receptor | mTORC1 axis modulated by SEL1L in CD8+ T cells | Affects T-cell homeostasis |
| mTORC1 | Signaling pathway influenced by SEL1L-mediated ERAD regulation | Integrates ERAD with T-cell metabolism |
| Nrf2 (NFE2L2) | Activated downstream of Keap1 ERAD | Promotes cancer cell survival |
| Fibrinogen | Biogenesis regulated by SEL1L-HRD1 ERAD | Hepatic inclusion formation |
| Autophagy machinery | Induction requires UBXD6 in macrophages | Innate immunity and inflammation |
| Cross-presentation machinery | Antigen export to cytosol involves ERAD | CD8+ T-cell activation |
How Is positive regulation of ERAD pathway Regulated?
Positive regulation of ERAD is controlled at multiple levels. The SEL1L-HRD1 complex itself is subject to quality control, as mutations in HRD1 transmembrane domains affect ERAD efficiency. Signaling pathways such as the PERK branch of the unfolded protein response and mTORC1 modulate ERAD activity in immune cells. Deubiquitinases like OTUB1 can counteract ERAD by removing ubiquitin from substrates such as PD-L1, while E3 ligases like TRIM25 promote ERAD of Keap1. In macrophages, UBXD6 is required for autophagy induction and inflammation control, indicating cross-talk between ERAD and autophagy. These regulatory layers ensure that ERAD capacity matches cellular demand.
positive regulation of ERAD pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OTUB1 | Cancer immunosuppression via PD-L1 stabilization | Knockout or point-mutation in cancer cell lines; PD-L1 degradation assays |
| TRIM25 | Hepatocellular carcinoma growth via Keap1-Nrf2 | Knockout in HCC cell lines; Nrf2 reporter assays |
| B4GALT5 | Pancreatic ductal adenocarcinoma immune evasion via MHC-I downregulation | Knockout in PDAC cells; CD8+ T-cell co-culture |
| SEL1L | Hepatic inclusions and fibrinogen biogenesis; CD8+ T-cell survival | Liver-specific knockout; T-cell knockout models |
| UBXD6 | Macrophage autophagy and inflammation | Knockout in macrophages; autophagy flux assays |
Cancer and immune evasion
Positive regulation of ERAD is exploited by cancer cells to evade immunity. OTUB1 prevents ERAD-mediated degradation of PD-L1, promoting immunosuppression. TRIM25 targets Keap1 for ERAD, activating Nrf2 and supporting hepatocellular carcinoma growth. In pancreatic ductal adenocarcinoma, B4GALT5 downregulates MHC-I through ERAD, limiting CD8+ T-cell responses. These findings position ERAD regulators as potential therapeutic targets.
Hepatic proteinopathies
SEL1L-HRD1 ERAD regulates hepatic inclusions and fibrinogen biogenesis, and its dysfunction can lead to accumulation of misfolded proteins in the liver. This links positive regulation of ERAD to liver disease and protein aggregation disorders.
Immune homeostasis and inflammation
SEL1L preserves CD8+ T-cell survival by fine-tuning PERK signaling and the IL-15 receptor-mTORC1 axis. UBXD6 is essential for autophagy induction and inflammation control in macrophages. Dysregulation of ERAD positive regulators may therefore contribute to immune dysfunction and inflammatory diseases.
Antigen presentation and cross-presentation
ERAD activity influences antigen export to the cytosol during cross-presentation, which is critical for CD8+ T-cell activation. Modulating positive regulation of ERAD could affect vaccine responses and anti-tumor immunity.
From positive regulation of ERAD pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SEL1L affect hepatic fibrinogen biogenesis? | Liver-specific SEL1L knockout mouse or HepG2 knockout cells |
| Does OTUB1 regulate PD-L1 stability through ERAD? | OTUB1 knockout cancer cells with PD-L1 degradation assays |
| Does TRIM25-mediated Keap1 ERAD promote HCC growth? | TRIM25 knockout HCC cells and xenograft models |
| Does B4GALT5 downregulate MHC-I via ERAD in PDAC? | B4GALT5 knockout PDAC cells and CD8+ T-cell co-cultures |
| Does UBXD6 control autophagy in macrophages? | UBXD6 knockout macrophages with autophagy flux assays |
| How do HRD1 transmembrane mutations affect ERAD? | Point-mutation knock-in of HRD1 in ERAD reporter cells |
How to Study the positive regulation of ERAD pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Genetic selection | ERAD complex integrity and function | Screening HRD1 transmembrane domain mutations |
| Cross-presentation assay | Antigen export to cytosol and T-cell activation | Studying ERAD in immune surveillance |
| Proteomics | ERAD substrate identification and ubiquitination | Mapping ERAD networks |
| CRISPR knockout screen | Positive regulators of ERAD | Discovery of novel ERAD modulators |
| Autophagy flux assay | Autophagy induction | Macrophage inflammation studies |
| PD-L1 degradation assay | ERAD-mediated PD-L1 turnover | Cancer immunosuppression research |
| Nrf2 reporter assay | Keap1 ERAD and Nrf2 activation | Hepatocellular carcinoma studies |
| MHC-I surface staining | MHC-I downregulation via ERAD | PDAC immune evasion studies |
Genetic selection and reporter assays
Positive genetic selection for transmembrane domain mutations in HRD1 has been used to dissect ERAD complex integrity. Reporter assays that measure degradation of misfolded substrates can quantify ERAD activity.
Cross-presentation and antigen export assays
Cross-presentation assays measure antigen export to the cytosol and CD8+ T-cell activation, providing functional readouts for ERAD-dependent antigen processing.
Proteomics and ubiquitin analysis
Mass spectrometry-based proteomics can identify ERAD substrates and ubiquitination sites. OTUB1-mediated deubiquitination of PD-L1 and TRIM25-mediated ubiquitination of Keap1 are examples where ubiquitin dynamics are central.
CRISPR screens and imaging
CRISPR knockout screens can identify positive regulators of ERAD, while fluorescence imaging of ERAD reporters allows spatial and temporal analysis. These approaches are complemented by autophagy flux assays for UBXD6.
How CRISPR Can Be Used to Study GO:1904294 positive regulation of ERAD pathway
Knockout
CRISPR knockout of genes such as SEL1L, OTUB1, TRIM25, B4GALT5, or UBXD6 can reveal their roles in positive regulation of ERAD. For example, OTUB1 knockout increases PD-L1 degradation, confirming its role in preventing ERAD.
Point Mutation
Point mutations in HRD1 transmembrane domains have been selected genetically to study ERAD complex integrity. CRISPR point-mutation models can mimic disease-associated variants in ERAD regulators.
Knock-in
Knock-in of tagged ERAD components (e.g., SEL1L-HA) allows tracking of complex assembly and substrate interactions in live cells.
Overexpression
Overexpression of positive regulators such as TRIM25 or B4GALT5 can enhance ERAD of Keap1 or MHC-I, respectively, providing gain-of-function models for cancer and immune studies.
How EDITGENE Supports positive regulation of ERAD pathway Research
Researchers studying positive regulation of ERAD pathway-related genes often need to determine whether a candidate gene is causally involved in ERAD flux, substrate degradation, or disease phenotypes. EDITGENE provides CRISPR-based cell model services to enable such causal experiments with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of ERAD pathway research.
Frequently Asked Questions About positive regulation of ERAD pathway
What is GO:1904294 positive regulation of ERAD pathway?
GO:1904294 is a Gene Ontology biological process term describing any process that activates or increases the frequency, rate, or extent of ERAD (endoplasmic reticulum-associated degradation).
What genes are involved in positive regulation of ERAD pathway?
Key genes include SEL1L, HRD1 (SYVN1), OTUB1, TRIM25, UBXD6, and B4GALT5, as shown in studies of ERAD regulation and disease.
How does positive regulation of ERAD affect cancer?
It can promote cancer immunosuppression by stabilizing PD-L1 via OTUB1, activating Nrf2 via TRIM25-mediated Keap1 degradation, and downregulating MHC-I via B4GALT5.
What is the role of SEL1L in ERAD?
SEL1L is a core component of the SEL1L-HRD1 ERAD complex that regulates hepatic inclusions, fibrinogen biogenesis, and CD8+ T-cell survival.
How is ERAD positively regulated in immune cells?
SEL1L fine-tunes PERK signaling and the IL-15 receptor-mTORC1 axis in CD8+ T cells, while UBXD6 is essential for autophagy induction and inflammation control in macrophages.
What methods are used to study positive regulation of ERAD?
Methods include genetic selection for HRD1 mutations, cross-presentation assays, proteomics, CRISPR screens, and autophagy flux assays.
Can CRISPR be used to study ERAD pathway regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect ERAD regulator function.
What diseases are linked to ERAD dysregulation?
ERAD dysregulation is linked to cancer immune evasion, hepatic proteinopathies, and immune homeostasis disorders.
What is the difference between ERAD and autophagy?
ERAD degrades misfolded ER proteins via the proteasome, while autophagy degrades cytoplasmic components via lysosomes; UBXD6 links both processes in macrophages.
How does OTUB1 regulate PD-L1 through ERAD?
OTUB1 deubiquitinates PD-L1, preventing its ERAD-mediated degradation and promoting cancer immunosuppression.
Conclusion
GO:1904294 positive regulation of ERAD pathway is a critical biological process that enhances the clearance of misfolded proteins from the endoplasmic reticulum. Its experimental dissection has revealed key roles for SEL1L-HRD1, OTUB1, TRIM25, UBXD6, and B4GALT5 in cancer, immunity, and hepatic biology. Understanding how these regulators are controlled offers opportunities for therapeutic intervention. Researchers can leverage CRISPR-based knockout, point-mutation, knock-in, and overexpression models to causally test ERAD regulators in disease contexts. EDITGENE provides end-to-end services to accelerate such discoveries.
References
- 1. Song Z et al.. 2024. Regulation of hepatic inclusions and fibrinogen biogenesis by SEL1L-HRD1 ERAD.. Nat Commun 15(1):9244 PMID: 39455574
- 2. Liu Y et al.. 2020. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.. Nat Commun 11(1):348 PMID: 31953436
- 3. Kim YJ et al.. 2024. Ubiquitin regulatory X (UBX) domain-containing protein 6 is essential for autophagy induction and inflammation control in macrophages.. Cell Mol Immunol 21(12):1441-1458 PMID: 39438692
- 4. Gao Y et al.. 2023. SEL1L preserves CD8(+) T-cell survival and homeostasis by fine-tuning PERK signaling and the IL-15 receptor-mediated mTORC1 axis.. Cell Mol Immunol 20(10):1232-1250 PMID: 37644166
- 5. Gros M et al.. 2019. Regulation of Antigen Export to the Cytosol During Cross-Presentation.. Front Immunol 10:41 PMID: 30745902
- 6. Zhu D et al.. 2021. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1.. Cell Death Differ 28(6):1773-1789 PMID: 33328570
- 7. Xing X et al.. 2025. B4GALT5 inhibits CD8(+) T-cell response by downregulating MHC-I level through ERAD pathway in PDAC.. J Immunother Cancer 13(5) PMID: 40316305
- 8. Nakatsukasa K et al.. 2022. A positive genetic selection for transmembrane domain mutations in HRD1 underscores the importance of Hrd1 complex integrity during ERAD.. Curr Genet 68(2):227-242 PMID: 35041076
